Beijing Konruns Pharmaceutical Co Ltd
SSE:603590
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CN |
|
Beijing Konruns Pharmaceutical Co Ltd
SSE:603590
|
6.6B CNY |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
989.2B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
573.4B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
281.1B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
302.9B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
230.9B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.1B GBP |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
154B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
125.3B USD |
Loading...
|
Market Distribution
| Min | -409 046.1% |
| 30th Percentile | -1.4% |
| Median | 4.2% |
| 70th Percentile | 10.3% |
| Max | 876.4% |
Other Profitability Ratios
Beijing Konruns Pharmaceutical Co Ltd
Glance View
Beijing Konruns Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of new drugs, with a focus on new special drugs. The company is headquartered in Beijing, Beijing and currently employs 473 full-time employees. The company went IPO on 2018-08-27. The firm's main product Suling belongs to the haemocoagulase drug that activates the coagulation process, which is mainly used for hemostasis of superficial wound bleeding in surgical operations as well as the bleeding caused by postoperative, trauma and disease. The Company’s present products under research include a range of innovative and generic drugs for tumors and blood. The firm mainly distributes its products in the domestic market.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Beijing Konruns Pharmaceutical Co Ltd is 4.5%, which is below its 3-year median of 12.3%.
Over the last 3 years, Beijing Konruns Pharmaceutical Co Ltd’s Operating Margin has decreased from 9.9% to 4.5%. During this period, it reached a low of 2.8% on Mar 31, 2025 and a high of 21.9% on Sep 30, 2023.
